Artiva Biotherapeutics, Inc.'s Quiet Period Set To Expire on August 28th (NASDAQ:ARTV)

Artiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) quiet period is set to end on Wednesday, August 28th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analyst Weigh In

ARTV has been the subject of several research analyst reports. Needham & Company LLC initiated coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a "buy" rating and a $23.00 price objective for the company. Wedbush initiated coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set an "outperform" rating and a $18.00 price objective for the company. Cantor Fitzgerald began coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set an "overweight" rating and a $23.00 price objective for the company. Jefferies Financial Group began coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a "buy" rating and a $21.00 price target for the company. Finally, TD Cowen began coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a "buy" rating for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $21.25.

Artiva Biotherapeutics Trading Down 0.2 %

Shares of ARTV stock traded down $0.02 during trading hours on Wednesday, hitting $10.07. The company had a trading volume of 35,447 shares, compared to its average volume of 130,163. Artiva Biotherapeutics has a 12 month low of $10.00 and a 12 month high of $16.00.

Insider Activity

In related news, Director Yong-Jun Huh acquired 2,083,332 shares of the stock in a transaction dated Monday, July 22nd. The shares were bought at an average cost of $12.00 per share, for a total transaction of $24,999,984.00. Following the purchase, the director now owns 3,306,900 shares in the company, valued at approximately $39,682,800. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other Artiva Biotherapeutics news, major shareholder Global Strategic Fund I. Venbio purchased 416,666 shares of the firm's stock in a transaction that occurred on Monday, July 22nd. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $4,999,992.00. Following the transaction, the insider now directly owns 1,936,637 shares in the company, valued at $23,239,644. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Yong-Jun Huh purchased 2,083,332 shares of the firm's stock in a transaction that occurred on Monday, July 22nd. The shares were acquired at an average price of $12.00 per share, for a total transaction of $24,999,984.00. Following the completion of the transaction, the director now owns 3,306,900 shares in the company, valued at $39,682,800. The disclosure for this purchase can be found here.

About Artiva Biotherapeutics

Artiva Biotherapeutics Inc is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc is based in SAN DIEGO.